49.57
-2.24 (-4.32%)
| Previous Close | 51.81 |
| Open | 51.61 |
| Volume | 2,731,138 |
| Avg. Volume (3M) | 1,981,242 |
| Market Cap | 9,581,109,248 |
| Price / Earnings (TTM) | 35.66 |
| Price / Earnings (Forward) | 10.86 |
| Price / Sales | 3.30 |
| Price / Book | 1.68 |
| 52 Weeks Range | |
| Earnings Date | 3 Aug 2026 |
| Profit Margin | 17.76% |
| Operating Margin (TTM) | 30.05% |
| Diluted EPS (TTM) | 2.70 |
| Quarterly Revenue Growth (YOY) | 14.80% |
| Quarterly Earnings Growth (YOY) | 109.40% |
| Total Debt/Equity (MRQ) | 10.39% |
| Current Ratio (MRQ) | 5.52 |
| Operating Cash Flow (TTM) | 700.26 M |
| Levered Free Cash Flow (TTM) | 411.56 M |
| Return on Assets (TTM) | 6.38% |
| Return on Equity (TTM) | 9.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | BioMarin Pharmaceutical Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 1.38 |
|
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.77% |
| % Held by Institutions | 98.91% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 105.00 (Barclays, 111.82%) | Buy |
| Median | 90.00 (81.56%) | |
| Low | 55.00 (HC Wainwright & Co., 10.95%) | Hold |
| Average | 87.38 (76.28%) | |
| Total | 7 Buy, 1 Hold | |
| Avg. Price @ Call | 61.12 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 11 Mar 2026 | 85.00 (71.47%) | Buy | 60.32 |
| Barclays | 04 Mar 2026 | 105.00 (111.82%) | Buy | 60.43 |
| HC Wainwright & Co. | 02 Mar 2026 | 55.00 (10.95%) | Hold | 59.74 |
| 25 Feb 2026 | 55.00 (10.95%) | Hold | 61.44 | |
| Canaccord Genuity | 26 Feb 2026 | 104.00 (109.80%) | Buy | 61.11 |
| Bernstein | 25 Feb 2026 | 94.00 (89.63%) | Buy | 61.44 |
| Guggenheim | 25 Feb 2026 | 86.00 (73.49%) | Buy | 61.44 |
| Oppenheimer | 24 Feb 2026 | 95.00 (91.65%) | Buy | 62.62 |
| Wells Fargo | 18 Feb 2026 | 75.00 (51.30%) | Buy | 61.83 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |